Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Breast Neoplasms 1

Interventions

Ipilimumab 6pembrolizumab 5Nivolumab 5Dacarbazine 5CTLA-4 Antigen 4Carboplatin 3Bevacizumab 3relatlimab 2aflibercept 2Temozolomide 2Ranibizumab 2Radiosurgery 2Paclitaxel 2Lenalidomide 2Immunoglobulin G 2Embolization, Therapeutic 2Disulfides 2Cyclophosphamide 2Colony-Stimulating Factors 2Albumin-Bound Paclitaxel 2AZD 6244 2130-nm albumin-bound paclitaxel 2utomilumab 1ulixertinib 1trametinib 1tebentafusp 1sotrastaurin 1sargramostim 1poly ICLC 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Uveal Melanoma × GSK2141795 × Clear all
NCT01979523 2026-04-13

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
42 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡